Use of Intravenous Acetaminophen to Reduce Opioid Use in Patients Undergoing Bariatric Surgery at a Community Teaching Hospital
Journal Title: Journal of Pharmaceutics & Pharmacology - Year 2014, Vol 2, Issue 2
Abstract
Purpose: The use of intravenous (IV) acetaminophen has been evaluated in several clinical trials and systematic reviews and has been shown to be an effective pain medication that can reduce the need for opioids. Recently, the Pharmacy and Therapeutics (P&T) committee at Atlanta Medical Center (AMC) approved an extension of the use of IV acetaminophen from one dose intra-operatively to four doses over 24 hours for 30 patients. The objective of this study was to compare the use of IV acetaminophen dosed at 1 g every 6 hours, to the previous use of 1 g for one dose at AMC in patients undergoing bariatric surgery. Methods: Patients were divided into two groups; control group consisting of patients who received one dose of IV acetaminophen in the operating room (OR) and the intervention group consisting of patients who received four doses of IV acetaminophen over a 24 hour period. The primary endpoint was the total amount of opioids required by patients over 24 hours measured in morphine equivalents. The secondary endpoints were the adverse effects and average pain scores. Results: The final sample consisted of 30 patients in each group. The total amount of opioids used by the intervention group was 28.3% lower than that of the control group. The average amount of opioids required by patients in the intervention group was 13.08 mg compared to 18.23 mg in the control group (p = 0.15). The only adverse event experienced within the groups was nausea/vomiting (p = 0.1). The average pain score reported by patients in the intervention group was 4.58 compared to 6.12 in the control group (p = 0.04). Conclusion: Although not powered to show statistical significance between groups, IV acetaminophen is associated with a reduction in opioid use, and improved pain scores over a 24 hour period. Adequately powered studies are needed to determine the long term benefits of acute opioid reduction.
Authors and Affiliations
C EeJay Enekwa
Keywords
Related Articles
- EP ID EP198025
- DOI 10.13188/2327-204X.1000009
- Views 97
- Downloads 0
Targeting the Endocannabinoid System for Neuroprotection: A 19F-NMR Study of a Selective FAAH Inhibitor Binding with an Anandamide Carrier Protein, HSA
Fatty acid amide hydrolase (FAAH), the enzyme involved in the inactivation of the endocannabinoid anandamide (AEA), is being considered as a therapeutic target for analgesia and neuroprotection. We have developed a brain...
Development of Controlled- Release Solid Dispersion Granules Containing a Poorly Water-Soluble Drug, Porous Calcium Silicate, and the Water-Soluble Polymer Polyvinylpyrrolidone
Objectives: This study sought to develop controlled-release solid dispersion granules containing a poorly water-soluble drug, porous calcium silicate (PCS), and a water-soluble polymer. Methods: Nifedipine (NIF) and ind...
A Review of Community Pharmacy-Based Pharmacologic Interventions and Methods for Smoking Cessation
Background: The aim of this study was to provide an overview of the published peer-reviewed literature related to community pharmacy-based smoking cessation counseling efforts in the United States and Canada. Methods: E...
Reactive Oxygen Species as β2-Adrenergic Receptor Signal Transducers
Reactive oxygen species (ROS), which include superoxide (O2−), hydrogen peroxide (H2O2), and the hydroxyl radical (OH.), have traditionally been cast as cellular byproducts, having benefit only for their microbicidal pro...
A Case of Suspected Drug Interaction Between Topiramate and Co-administered Clarithromycin/Pranlukast
Case description: A 4-year-old boy presented with tuberous sclerosis and symptomatic partial epilepsy of the upper right extremity. Topiramate was prescribed for the treatment of epilepsy, and seizure behavior was well c...